Sellas rises as blood cancer drug succeeds in early-stage study

Sellas Life Sciences

21/09/2023 16:35

** Shares of cancer drug developer Sellas Life Sciences
Group  SLS.O  rise 3.3% to $1.55   
    ** Co says its experimental drug to treat a group of blood
cancers met the main goal in an early-stage study
    ** The drug candidate, SLS009, produced up to 62% tumor
reduction in five out of 34 evaluable patients with
relapsed/refractory (r/r) lymphomas -SLS   
     ** Says the drug was well tolerated with no drug-related
fatalities at any dose level 
    ** Including session's moves, stock down ~34% YTD 

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))